Tregalizumab
Tregalizumab is an immunomodulator.[1] It is also known as BT-061. Tregalizumab binds to domain 2 of CD4,[2] and activates Regulatory T cells (Tregs).[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | CD4 |
Clinical data | |
Other names | BT-061 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
![]() ![]() |
References
- World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, Jonuleit H, Kubach J, Dingermann T, Radeke HH, Osterroth F, Uherek C, Czeloth N, Schüttrumpf J (April 2015). "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway". Immunol Cell Biol. 93 (4): 396–405. doi:10.1038/icb.2014.102. PMC 4407014.CS1 maint: multiple names: authors list (link)
- König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J (Jan 2016). "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells". Frontiers in Immunology. 7. doi:10.3389/fimmu.2016.00011. PMC 4724712.CS1 maint: multiple names: authors list (link)
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.